OFFER DOCUMENT SUMMARY

The following is a general summary of certain disclosures included in this Prospectus and is neither exhaustive, nor purports
to contain a summary of all the disclosures in the Red Herring Prospectus or this Prospectus when filed, or all details relevant
to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed
information appearing elsewhere in this Prospectus, including “Risk Factors”, “The Offer”, “Capital Structure”, “Objects of
the Offer”, “Industry Overview”, “Our Business”, “Financial Statements”, “Outstanding Litigation and Material
Developments”, “Offer Procedure” and “Description of Equity Shares and Terms of Articles of Association” on pages 29, 58,
75, 104, 125, 148, 209, 304, 338 and 355, respectively.

 

 

    

All references to the Selling Shareholders includes (a) the Investor Selling Shareholder, namely, PI Opportunities Fund — I;
and (b) the Other Selling Shareholders, namely, S. S. Pharma LLC, Natco Pharma Limited, Time Cap Pharma Labs Private
Limited, Shore Pharma LLC, A. Raghava Reddy, K Prakurthi, Navdeep Patyal, Sangeeta Raju, R. Venkat Reddy, TK Kurien,
Nithya Venkataramani, Atul Gupta, Manoj Jaiswal, Rahul Garg, Kollengode Ramanathan Lakshminarayana and Bijou Kurien
(collectively, the “Selling Shareholders”).

 

Summary of the] In terms of the Technopak Report, we are the second largest pharmacy retailer in India in terms of revenue from
primary business| operations and number of stores, as of financial year 2021. See “Industry Overview — Competitive Benchmarking —
ofour Company | Pharmacy Retail Market — Comparison of Certain Metrics of Players in the Pharmaceutical Retail Industry” on page
137. We offer a wide range of products, including (i) pharmaceutical and wellness products such as medicines, vitamins,
medical devices and test kits, and (ii) FMCG products such as home and personal care products, including toiletries,
baby care products, soaps and detergents and sanitizers. We were the first pharmacy retailer in India to offer an omni-
channel platform and continue to scale up our retail store network (Source: Technopak Report).

 

Summary of the| In terms of the Technopak Report, the pharmacy retail industry is expected to grow at a CAGR of 11% in the next four
industry in which| years, with FMCG products playing an increasingly important role in the product mix with sales contributions of up to
our —_ Company| 30% for modern organized pharmacy stores. As per the Technopak Report, the modern pharmacy retail segment is
operates estimated to grow at 27% CAGR, and faster than other segments within pharmacy retail. B&M stores adopting the
hyperlocal model and omnichannel retail platform is also emerging as important players in the pharmacy retail market.

 

Name of our|Gangadi Madhukar Reddy, Lone Furrow Investments Private Limited and Agilemed Investments Private Limited
Promoters

 

Offer size Offer of 17,573,342* Equity Shares of face value of &2 each for cash at a price of 796" per Equity Share (including a
premium of 2794 per Equity Share) (“Offer Price”) aggregating to 213,982.95 million (the “Offer”), comprising of a
Fresh Issue of 7,544,511 Equity Shares aggregating up to 26,000 million (The “Fresh Issue”) by our Company and an
Offer for Sale of 10,028,831 Equity Shares aggregating to 7,982.95 million (the “Offer for Sale”), comprising of
7,826,626 Equity Shares aggregating to 26,230 million by PI Opportunities Fund — I (“Investor Selling Shareholder”),
1,344,221 Equity Shares aggregating to 1,070.00 million by S. S. Pharma LLC, 402,010 Equity Shares aggregating to
3320.00 million by Shore Pharma LLC, 125,628 Equity Shares aggregating to 2100.00 million by Natco Pharma
Limited, 125,628 Equity Shares aggregating to 100.00 million by Time Cap Pharma Labs Private Limited, 89,547
Equity Shares aggregating to 271.28 million by A. Raghava Reddy, 53,115 Equity Shares aggregating to 242.28 million
by K Prakurthi, 27,135 Equity Shares aggregating to 221.60 million by Navdeep Patyal, 18,467 Equity Shares
aggregating to 214.70 million by Sangeeta Raju, 14,974 Equity Shares aggregating to 211.92 million by R. Venkat
Reddy, 276 Equity Shares aggregating to 8 0.22 million by TK Kurien, 251 Equity Shares aggregating to 20.20 million
by Nithya Venkataramani, 251 Equity Shares aggregating to 20.20 million by Atul Gupta, 251 Equity Shares
aggregating to 20.20 million by Manoj Jaiswal, 251 Equity Shares aggregating to 20.20 million by Rahul Garg, 100
Equity Shares aggregating to 20.08 million by Kollengode Ramanathan Lakshminarayana and 100 Equity Shares
aggregating to 20.08 million by Bijou Kurien (collectively, the “Other Selling Shareholders” and collectively with
the Investor Selling Shareholder are referred to as the “Selling Shareholders”)

‘The Offer includes a reservation of 69,637 Equity Shares, aggregating up to 50 million, for subscription by Eligible
Employees. Our Company and the Investor Selling Shareholder, in consultation with the BRLMs, may offer a discount
of 9.80% (equivalent of & 78 per Equity Share) to the Offer Price to Eligible Employees.

The Offer less the Employee Reservation Portion is the Net Offer. The Offer and Net Offer constitutes 14.72% and
14.67% of the post-Offer paid-up equity share capital of our Company.

“Subject to finalisation of the Basis of Allotment
AA discount of 278 per Equity Share was offered to Eligible Employees Bidding in the Employee Reservation

 

 

 

 

 

 

 

 

 

 

 

Portion
Objects of the| The objects for which the Net Proceeds from the Offer shall be utilized are as follows:
Offer (Zinmillion)
Particulars Amount @in million)
Investment into our Material Subsidiary, Optival for funding working capital 4,671.70
requirements of Optival
General corporate purposes 1,055.71
Total 5,727.41
Aggregate pre-|(a) The aggregate pre-Offer shareholding of our Promoters and Promoter Group as a percentage of the pre-Offer paid-
Offer shareholding up Equity Share capital of our Company is set out below:
of our Promoters
and Promoter
Group, and Selling

 

 

13
